Recombinant Anti-FHL1 antibody [EPR7520] (ab133661)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR7520] to FHL1
- Suitable for: WB, IHC-P
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-FHL1 antibody [EPR7520]
See all FHL1 primary antibodies -
Description
Rabbit monoclonal [EPR7520] to FHL1 -
Host species
Rabbit -
Tested applications
Suitable for: WB, IHC-Pmore details
Unsuitable for: Flow Cyt or ICC/IF -
Species reactivity
Reacts with: Human
Predicted to work with: Mouse, Rat -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- Human fetal muscle lysate; Human colon and muscle tissues
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at -20°C. Stable for 12 months at -20°C. -
Dissociation constant (KD)
KD = 1.01 x 10 -10 M Learn more about KD -
Storage buffer
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, 50% Tissue culture supernatant -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR7520 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab133661 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/1000 - 1/10000. Detects a band of approximately 32 kDa (predicted molecular weight: 36 kDa).
|
|
IHC-P |
1/100 - 1/250. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
|
Notes |
---|
WB
1/1000 - 1/10000. Detects a band of approximately 32 kDa (predicted molecular weight: 36 kDa). |
IHC-P
1/100 - 1/250. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. |
Target
-
Function
May have an involvement in muscle development or hypertrophy. -
Tissue specificity
Isoform 1 is highly expressed in skeletal muscle and to a lesser extent in heart, placenta, ovary, prostate, testis, small intestine, colon and spleen. Expression is barely detectable in brain, lung, liver, kidney, pancreas, thymus and peripheral blood leukocytes. Isoform 2 is expressed in brain, skeletal muscle and to a lesser extent in heart, colon, prostate and small intestine. Isoform 3 is expressed in testis, heart and skeletal muscle. -
Involvement in disease
Defects in FHL1 are the cause of X-linked dominant scapuloperoneal myopathy (SPM) [MIM:300695]. Scapuloperoneal syndrome (SPS) was initially described more than 120 years ago by Jules Broussard as 'une forme hereditaire d'atrophie musculaire progressive' beginning in the lower legs and affecting the shoulder region earlier and more severely than distal arm. The etiology of this condition remains unclear.
Defects in FHL1 are the cause of X-linked myopathy with postural muscle atrophy (XMPMA) [MIM:300696]. Myopathies are inherited muscle disorders characterized by weakness and atrophy of voluntary skeletal muscle, and several types of myopathy also show involvement of cardiac muscle. XMPMA is a distinct form of adult-onset X-linked recessive myopathy with several features in common with other myopathies, but the presentation of a pseudoathletic phenotype, scapuloperoneal weakness, and bent spine is unique and might render the clinical phenotype distinguishable from other myopathies.
Defects in FHL1 are the cause of X-linked severe early-onset reducing body myopathy (RBM) [MIM:300717]. RBM is a rare muscle disorder causing progressive muscular weakness and characteristic intracytoplasmic inclusions in myofibers. Clinical presentations of RBM have ranged from early onset fatal to childhood onset to adult onset cases.
Defects in FHL1 are the cause of X-linked childhood-onset reducing body myopathy (CO-RBM) [MIM:300718]. This disorder is allelic to severe early-onset reducing body myopathy (RBM) [MIM:300717]. -
Sequence similarities
Contains 3 LIM zinc-binding domains. -
Developmental stage
Elevated levels during postnatal muscle growth. -
Cellular localization
Cytoplasm; Cytoplasm. Nucleus and Nucleus. Cytoplasm > cytosol. Predominantly nuclear in myoblasts but is cytosolic in differentiated myotubes. - Information by UniProt
-
Database links
- Entrez Gene: 2273 Human
- Entrez Gene: 14199 Mouse
- Entrez Gene: 25177 Rat
- Omim: 300163 Human
- SwissProt: Q13642 Human
- SwissProt: P97447 Mouse
- SwissProt: Q9WUH4 Rat
- Unigene: 435369 Human
see all -
Alternative names
- bA535K18.1 antibody
- FHL 1 antibody
- FHL 1B antibody
see all
Images
-
Anti-FHL1 antibody [EPR7520] (ab133661) at 1/1000 dilution + Human fetal muscle tissue lysate at 10 µg
Secondary
HRP labelled Goat anti-Rabbit at 1/2000 dilution
Predicted band size: 36 kDa
Observed band size: 32 kDa why is the actual band size different from the predicted? -
Immunohistochemistry analysis of FHL1 in paraffin embedded Human colon tissue labelled with ab133661 at a 1/100 dilution.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
-
Immunohistochemistry analysis of FHL1 in paraffin embedded Human muscle tissue labelled with ab133661 at a 1/100 dilution.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (4)
ab133661 has been referenced in 4 publications.
- Liu Y et al. FHL1 Inhibits the Progression of Colorectal Cancer by Regulating the Wnt/ß-Catenin Signaling Pathway. J Cancer 12:5345-5354 (2021). PubMed: 34335951
- Shao Z et al. RNA Sequence Analyses throughout the Course of Mouse Cardiac Laminopathy Identify Differentially Expressed Genes for Cell Cycle Control and Mitochondrial Function. Sci Rep 10:6632 (2020). PubMed: 32313136
- Du Y et al. Effects of FHL1 and P21 on hypoxia-induced pulmonary vascular remodeling in neonatal rats. Exp Ther Med 14:4245-4253 (2017). PubMed: 29067108
- Hemming S et al. Identification of Novel EZH2 Targets Regulating Osteogenic Differentiation in Mesenchymal Stem Cells. Stem Cells Dev 25:909-21 (2016). PubMed: 27168161